Stop the Sticker Shock: The Gene Therapy Stop‑Loss Solution
Gene therapy is changing the way we think about healthcare and treatments for chronic diseases—and for self‑funded employers, it’s bringing serious financial shock potential. With many therapies priced between $2 million and $4 million per treatment, a single claim can throw an entire plan year off balance [1–4]. Additionally, as the number of FDA‑approved cellular and gene therapies keeps climbing, traditional stop‑loss coverage isn’t built to handle this level of volatility anymore [5, 6].